IP Verse

Nanoparticles, Process For Preparation And Use Thereof As Carrier For Amphipatic Of Hydrophobic Molecules In Fields Of Medicine Including Cancer Treatment And Food Related Compounds - EP2750683

The patent EP2750683 was granted to Croda on Jan 6, 2021. The application was originally filed on Oct 1, 2012 under application number EP12781489A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2750683

CRODA
Application Number
EP12781489A
Filing Date
Oct 1, 2012
Status
Patent Maintained As Amended
Dec 4, 2020
Grant Date
Jan 6, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

NOVAVAXDec 20, 2018NOVITAS PATENT -
NOVAVAXDec 20, 2018NOVITAS PATENT AB -

Patent Citations (48) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONDE2124023
DESCRIPTIONEP0109942
DESCRIPTIONEP0111058
DESCRIPTIONEP0122707
DESCRIPTIONEP0137145
DESCRIPTIONEP0180564
DESCRIPTIONEP0242380
DESCRIPTIONEP0253738
DESCRIPTIONEP0253739
DESCRIPTIONEP0321122
DESCRIPTIONEP0363227
DESCRIPTIONEP0436620
DESCRIPTIONEP0698611
DESCRIPTIONEP0902015
DESCRIPTIONEP1539231
DESCRIPTIONEP1800564
DESCRIPTIONGB1235022
DESCRIPTIONUS2006121065
DESCRIPTIONUS2802005
DESCRIPTIONUS3046301
DESCRIPTIONUS3803124
DESCRIPTIONUS4020270
DESCRIPTIONUS4046878
DESCRIPTIONUS4307100
DESCRIPTIONUS4377687
DESCRIPTIONUS5821337
DESCRIPTIONWO02080981
DESCRIPTIONWO2004004762
DESCRIPTIONWO2004030696
DESCRIPTIONWO2005002620
DESCRIPTIONWO2008063129
DESCRIPTIONWO2011005183
DESCRIPTIONWO9209589
DESCRIPTIONWO9222653
DESCRIPTIONWO9302094
DESCRIPTIONWO9404679
DESCRIPTIONWO9611711
DESCRIPTIONWO9730728
INTERNATIONAL-SEARCH-REPORTUS5679354
INTERNATIONAL-SEARCH-REPORTWO2004004762
INTERNATIONAL-SEARCH-REPORTWO2005002620
OPPOSITIONUS4578269
OPPOSITIONUS5679354
OPPOSITIONWO02080981
OPPOSITIONWO2004004762
OPPOSITIONWO2005002620
OPPOSITIONWO2014163558
OPPOSITIONWO9221331

Non-Patent Literature (NPL) Citations (36) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- A. ESMAT ABOU-ARAB; AZZA ABOU-ARAB; M.FERIAL ABU-SALEM, "Physico-chmical assessment of natural sweeteners steviosides produced from Stevia rebaudiana bertoni", AFRICAN JOURNAL OF FOOD SCIENCE, (201005), vol. 4, no. 5, pages 269 - 281-
DESCRIPTION- CHAIWAT BOONKAEWWANT; CHAIVAT TOSKULKAO; MOLVIBHA VONGSAKUL, "AntiInflammatory and Immunomodulatory Activities of Stevioside and Its Metabolite Steviol on THP-1 Cells", J. AGRIC. FOOD CHEM., (2006), vol. 54, pages 785 - 789-
DESCRIPTION- ELIASSON DG; EL BAKKOURI K; SCHON K; RAMNE A; FESTJENS E; LOWENADLER B; FIERS W; SAELENS X, "Lycke N.CTAI-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine", VACCINE, (20080110), vol. 26, no. 9, pages 1243 - 52-
DESCRIPTION- "ISCOM Technology", LÖVGREN; MOREIN, Methods in Molecular Medicine, HUMANA PRESS, INC., (2000), vol. 42, pages 239 - 258-
DESCRIPTION- MOWAT, A.M.; DONACHIE, A.M.; JAGEWALLL, S.; SCHON, K.; LOWENADLER, B.; DALSGAARD, K. ET AL., "CTAI-DD-immune stimulating complex: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen", J. IMMUNOL, (2001), vol. 167, no. 6, pages 3398 - 3405-
DESCRIPTION- "New ISCOMs meet unsettled vaccine demands", MOREIN B; HU K; LOVGREN K; D'HONDT E., Vaccine Adjuvants and Delivery Systems, JOHN WILEY & SONS, INC., (2007), pages 191 - 222-
DESCRIPTION- REMINGTON, Remington's Pharmaceutical Sciences, 18th Edition,, MACK PUBLISHING COMPANY-
DESCRIPTION- "Review Liposomes Preparation Methods Mohammad Riaz Faculty of Pharmacy", PAKISTAN PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, (199601), vol. 19, no. 1, pages 65 - 77-
DESCRIPTION- DAVIS MT; PRESTON JF., "A simple modified carbodiimide method for conjugation of small- molecular-weight compounds to immunoglobulin G with minimal protein crosslinking", ANAL BIOCHEM., (19810915), vol. 116, no. 2, doi:doi:10.1016/0003-2697(81)90380-8, pages 402 - 7, XP024826498
DESCRIPTION- KERSTEN, G.F.A.; SPIEKSTRA, A.; BEUVERY, E.C.; CROMELIN D.J.A., "On the structure of immune-stimulating saponin lipid complexes (ISCOMs", BBA, (1991), vol. 1062, doi:doi:10.1016/0005-2736(91)90388-O, pages 165 - 171, XP023576304
DESCRIPTION- BLAIR AH; GHOSE TI, "Linkage of cytotoxic agents to immunoglobulins", J IMMUNOL METHODS, (19830429), vol. 59, no. 2, doi:doi:10.1016/0022-1759(83)90024-8, pages 129 - 43, XP023900608
DESCRIPTION- GHOSE TI; BLAIR AH; KULKARNI PN, "Preparation of antibody-linked cytotoxic agents", METHODS ENZYMOL., (1983), vol. 93, doi:doi:10.1016/S0076-6879(83)93050-1, pages 280 - 333, XP008016408
DESCRIPTION- LYCKE, N., "From toxin to adjuvant: The rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM", CELL MICROBIOL, (2004), vol. 6, no. 1, doi:doi:10.1046/j.1462-5822.2003.00338.x, pages 23 - 32, XP002431449
DESCRIPTION- KEFEI HU; SAIDEH BERENJIAN; ROLF LARSSON; JOACHIM GULLBO; PETER NYGREN; TANJA L6VGREN; BROR MOREIN, "Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index", INTERNATIONAL JOURNAL OF NANOMEDICINE, (201001), vol. 2010, no. 5, doi:doi:10.2147/IJN.S7879, pages 51 - 62, XP009166265
OPPOSITION- BURKE et al., "Surface areas of naturally occurring lipid classes and the quantitative microdetermination of lipids", Journal of Lipid Research, (19730000), vol. 14, pages 9 - 15, XP055553850-
OPPOSITION- COPLAND et al., "Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes", International Journal of Pharmaceutics, (20000000), vol. 196, pages 135 - 139-
OPPOSITION- KERSTEN et al., "Incorporation of the Major Outer Membrane Protein of Neisseria gonorrhoeae in Saponin-Lipid Complexes (Iscoms): Chemical Analysis, Some Structural Features, and Comparison of Their Immunogenicity with Three Other Antigen Delivery Systems", Infection and Immunity, (19880200), vol. 56, no. 2, pages 432 - 438, XP000885502-
OPPOSITION- KERSTEN et al., "On the structure of immune-stimulating saponin -lipid complexes iscoms)", Biochimica et Biophysica Acta, (19910000), vol. 1062, pages 165 - 171-
OPPOSITION- LENDEMANS et al., "On the dilution behaviour of immuno-stimulating complexes (ISCOMs)", Pharmazie, (20060000), vol. 61, pages 689 - 695, XP055553844-
OPPOSITION- LÖVGREN et al., "The requirement of lipids for the formation of immunostimulating complexes (iscoms)", Biotechnology and Applied Biochemistry, (19880000), vol. 10, no. 2, pages 161 - 172, XP009140879-
OPPOSITION- SJÖLANDER et al., "ISCOMs: an adjuvant with multiple functions", Journal of Leucocyte Biology, (19981200), vol. 64, no. 6, pages 713 - 723, XP009052659-
OPPOSITION- KERSTEN et al., "On the structure of immune-stimulating saponin -lipid complexes iscoms)", Biochimica et Biophysica Acta, (19910000), vol. 1062, pages 165 - 171, XP002128948
OPPOSITION- KERSTEN et al., "Liposomes and ISCOMS as vaccine formulations", Biochimica et Biophysica Acta, (19950717), vol. 1241, pages 117 - 138, XP000885510
OPPOSITION- OZEL et al., "Quaternary structure of the immunostimulating complex (Iscom)", Journal of Ultrastructure and Molecular Structure Research, (19890000), vol. 102, pages 240 - 248, XP024875118
OPPOSITION- DEMANA et al., "Pseudo-ternary phase diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by the lipid-film hydration method", International Journal of Pharmaceutics, (20040000), vol. 270, pages 229 - 239, XP055553888
OPPOSITION- DEMANA et al., "Incorporation of ovalbumin into ISCOMs and related colloidal particles prepared by the lipid film hydration method", International Journal of Pharmaceutics, (20040000), vol. 278, pages 263 - 274, XP055553895
OPPOSITION- PHAM et al., "Preparation of immuno-stimulating complexes (ISCOMs) by ether injection", International Journal of Pharmaceutics, (20060000), vol. 310, no. 1-2, pages 196 - 202, XP005304255
OPPOSITION- DEMANA et al., "Quil A-lipid powder formulations releasing ISCOMs and related colloidal stuctures upon hydration", Journal of Controlled Release, (20050000), vol. 103, pages 45 - 59, XP004745755
OPPOSITION- LUCY et al., "Structure and assembly of macromolecular lipid complexes composed of globular micelles", J. Mol. Bio., (19640000), vol. 8, pages 727 - 748+10pp, XP026059681
OPPOSITION- STITTELAAR et al., "In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components", Vaccine, (20000000), vol. 18, no. 23, pages 2482 - 2493, XP004195913
OPPOSITION- COPLAND et al., "Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes", International Journal of Pharmaceutics, (20000000), vol. 196, pages 135 - 139, XP002349821
OPPOSITION- MADSEN et al., "In Vitro Cutaneous Application of ISCOMs on Human Skin Enhances Delivery of Hydrophobic Model Compounds Through the Stratum Corneum", The AAPS Journal, (20091200), vol. 11, no. 4, pages 728 - 739, XP055553933
OPPOSITION- LENDEMANS et al., "lmmuno-stimulating complexes prepared by ethanol injection", Journal of Pharmacy and Pharmacology, (20050000), vol. 57, pages 729 - 733, XP055553918
OPPOSITION- HU et al., "Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index", International Journal of Nanomedicine, (20100000), vol. 5, pages 51 - 62, XP009166265
OPPOSITION- PHAM et al., "Saponins from Quillaja saponaria Molina: Isolation, Characterization and Ability to Form Immuno Stimulatory Complexes (ISCOMs)", Current Drug Delivery, (20060300), vol. 3, no. 4, pages 389 - 397, XP055553908
OPPOSITION- LIPPERT et al., "Current Status of Methods to Assess Cancer Drug Resistance", International Journal of Medical Sciences, (20110323), vol. 8, no. 3, pages 245 - 253, XP055553855

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents